Abstract
Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Mini-Reviews in Medicinal Chemistry
Title:Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Volume: 17 Issue: 1
Author(s): Hao Liu, Haiyan Wang, Dingcheng Xiang and Wangang Guo
Affiliation:
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Abstract: Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Export Options
About this article
Cite this article as:
Liu Hao, Wang Haiyan, Xiang Dingcheng and Guo Wangang, Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity, Mini-Reviews in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1389557516666160621083659
DOI https://dx.doi.org/10.2174/1389557516666160621083659 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Endogenous Cardiotonics: Search and Problems
Cardiovascular & Hematological Disorders-Drug Targets The Proteasome in Health and Disease
Current Pharmaceutical Design Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Association Between Hypothyroidism and Takotsubo Cardiomyopathy: Analysis of Nationwide Inpatient Sample Database
Reviews on Recent Clinical Trials Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Antioxidant Therapy Against Trypanosome Infections: A Review Update
Current Topics in Medicinal Chemistry Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry